Evaxion announces business update and full year 2025 financial results
Evaxion Biotech A/S - American Depositary Share (EVAX)
Company Research
Source: GlobeNewswire
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces full year 2025 financial results. Business highlights2025 was a transformational year for Evaxion with significant strengthening of our fundamental business both strategically, scientifically and financially through achievement of several milestones. Highlights include: The historic licensing of our infectious disease vaccine candidate EVX-B3 by MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA)Unprecedented two-year phase 2 data for our personalized cancer vaccine candidate EVX-01 demonstrating impressive clinical outcomesReplenishing of our R&D pipeline adding EVX-04, an off-the-shelf vaccine candidate for acute myeloid leukemia (AML), and EVX-B4, a prophylactic vaccine candidate targeting Group A StreptococcusCollaborating with the Gates Foundation to design ne
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion Biotech A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion plans to file 2025 annual report later todayGlobeNewswire
- Evaxion to announce business update and full year 2025 financial results on March 5, 2026GlobeNewswire
- Evaxion A/S (NASDAQ:EVAX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Evaxion expands AI-Immunology™ platform into autoimmune diseasesGlobeNewswire
- Evaxion A/S (NASDAQ:EVAX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
EVAX
Sec Filings
- 3/5/26 - Form 6-K
- 3/5/26 - Form 20-F
- 3/5/26 - Form 6-K
- EVAX's page on the SEC website